相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation
T. Caballero-Velazquez et al.
BONE MARROW TRANSPLANTATION (2020)
Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP
Patrick J. Hayden et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2020)
Current Status of Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma
Vishal Jindal et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2020)
CAR T and CAR NK cells in multiple myeloma: Expanding the targets
Urvi A. Shah et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2020)
Relapse after Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Survival Outcomes and Factors Influencing Them
Saurabh Chhabra et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation
Luciano J. Costa et al.
BONE MARROW TRANSPLANTATION (2020)
Treosulfan conditioning for allogeneic transplantation in multiple myeloma - improved overall survival in first line haematopoietic stem cell transplantation - a large retrospective study by the Chronic Malignancies Working Party of the EBMT
Charlotte Gran et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement
Wilson I. Gonsalves et al.
BONE MARROW TRANSPLANTATION (2019)
Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life
Christine Greil et al.
HAEMATOLOGICA (2019)
Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma
Enrico Maffini et al.
HAEMATOLOGICA (2019)
Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma
Lucia Lopez-Corral et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
The use of bispecific antibodies to optimize the outcome of patients with acute leukemia, lymphoma and multiple myeloma after SCT
Hermann Einsele et al.
BONE MARROW TRANSPLANTATION (2019)
Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis
Stefan Knop et al.
LEUKEMIA (2019)
Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens
Hossein Maymani et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
Francesca Gay et al.
HAEMATOLOGICA (2018)
From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
Francesca Gay et al.
HAEMATOLOGICA (2018)
Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma
Luisa Giaccone et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival
Myo Htut et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation
Avichai Shimoni et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. Moreau et al.
ANNALS OF ONCOLOGY (2017)
Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features
Leo Rasche et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution
Laurens E. Franssen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party
M. Sobh et al.
LEUKEMIA (2016)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
Madan H. Jagasia et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation
Shernan G. Holtan et al.
BLOOD (2015)
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Allogeneic Hematopoietic Cell Transplantation from Unrelated Donors in Multiple Myeloma: Study from the Italian Bone Marrow Donor Registry
Roberto Passera et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Impact of High-Risk Cytogenetics and Achievement of Molecular Remission on Long-Term Freedom from Disease after Autologous-Allogeneic Tandem Transplantation in Patients with Multiple Myeloma
Nicolaus Kroeger et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study
Gosta Gahrton et al.
BLOOD (2013)
Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients
N. Kroeger et al.
BONE MARROW TRANSPLANTATION (2013)
Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation
Simona Iacobelli
BONE MARROW TRANSPLANTATION (2013)
Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study
Christine Wolschke et al.
EXPERIMENTAL HEMATOLOGY (2013)
Allogeneic Stem Cell Transplantation in Multiple Myeloma Relapsed after Autograft: A Multicenter Retrospective Study Based on Donor Availability
Francesca Patriarca et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire
Damien Roos-Weil et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up
Bo Bjorkstrand et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial
Amrita Krishnan et al.
LANCET ONCOLOGY (2011)
Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Hematologic Malignancies After Dose-Escalated Treosulfan/Fludarabine Conditioning
Jochen Casper et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Defining the Intensity of Conditioning Regimens: Working Definitions
Andrea Bacigalupo et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma
Laura Rosinol et al.
BLOOD (2008)
Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma
M. Schmidt-Hieber et al.
BONE MARROW TRANSPLANTATION (2007)
A comparison of allografting with autografting for newly diagnosed myeloma
Benedetto Bruno et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status
Nicolaus Kroeger et al.
EXPERIMENTAL HEMATOLOGY (2006)
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma
F Garban et al.
BLOOD (2006)
Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma
S Gerull et al.
BONE MARROW TRANSPLANTATION (2005)
Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation
JA Pérez-Simón et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe
A Urbano-Ispizua et al.
BONE MARROW TRANSPLANTATION (2002)
分享论文
